Melanoma-associated antigen 3 (MAGE-A3) peptide–HLA complex (MAGE-A3/HLA)

The Melanoma-associated antigen 3 (MAGE-A3) peptide–HLA complex is a critical target in the field of adoptive T-cell therapy and cancer immunotherapy. MAGE-A3 is a member of the cancer-testis antigen family, which is highly expressed in various solid tumors but restricted in normal tissues to the immune-privileged testis and placenta, making it an ideal target for minimizing systemic toxicity (Morgan et al., 2013, J Clin Oncol). Intracellular MAGE-A3 is processed into specific peptides, such as EVDPIGHLY or KVAELVHFL, which are presented on the cell surface by Human Leukocyte Antigen (HLA) molecules like HLA-A*01 or HLA-A*02. Therapeutic approaches utilize engineered T-cell receptors (TCRs) designed to recognize these specific peptide-MHC complexes with high affinity to induce a potent anti-tumor immune response. However, the clinical development of MAGE-A3-targeted TCRs has been historically complicated by severe safety issues. Early trials reported fatal toxicities when engineered TCRs cross-reacted with MAGE-A12 in the central nervous system or the muscle protein Titin in the heart, highlighting the extreme sensitivity required for TCR specificity (Linette et al., 2013, Blood). Current research focuses on refining TCR affinity and specificity to target MAGE-A3/A6 while avoiding these critical off-target tissues.

Other names

T-cell receptors specific for MAGE-A3 peptide–HLA complexesMAGE-A3 antigenMAGE-A3 peptide-MHC complexMAGEA3-HLA-A*01MAGEA3-HLA-A*02Antigen MAGE-A3

Engineered T-cell receptors (TCRs) or bispecific TCR molecules bind specifically to the MAGE-A3 peptide presented by HLA molecules on the surface of tumor cells, leading to T-cell activation, cytokine release, and targeted lysis of the cancer cell.